Value Investing: 1 Pharma Stock to Buy in June 2021

IMV (TSX:IMV)(NASDAQ:IMV) is a biopharmaceutical company that gives patients with hard-to-treat cancers a chance to enjoy a long and healthy life.

| More on:
stock market

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more

IMV (TSX:IMV)(NASDAQ:IMV) is a biopharmaceutical company focused on improving the treatment of cancer. The company gives patients with hard-to-treat cancers a chance to enjoy a long and healthy life. IMV uses a drug delivery platform (DPX) technology, to achieve targeted specific, and sustainable immune activation.

The company is developing a portfolio of DPX-based immunotherapies that address unmet medical needs. IMV’s lead product candidate, DPX-Survivac, is a pipeline in a product that generates sustained and targeted immune responses against Survivin, a tumor-associated protein. With the financial support of the Canadian government, IMV also initiated the development of DPX-COVID-19, a vaccine candidate using the DPX platform.

Animal health research

IMV commenced operations in March 2000 based on animal health research pioneered at Dalhousie  University in Halifax, Nova Scotia, when it was contracted by a government entity to develop a contraceptive to control the seal population. The company was able to develop a contraceptive and delivery system that demonstrated effectiveness such that 10 years after treatment, 90% of seals were still contracepted after a single dose.

Developing various technologies

From 2000 to 2008, the company concentrated IMV’s research efforts on animal contraception for both wildlife and companion animals, while also working on vaccines for infectious diseases in livestock. Over those years the company continued to develop various technologies and began exploring potential new human applications. This research eventually led to acquiring surviving cancer targets from Merck (NYSE:MRK).

Treatment of human cancers

Using traditional vaccine delivery technology, Merck had been unable to generate optimal T-cell activation. By reformulating cancer targets in the company’s DPX delivery platform, IMV saw different results in preclinical research highlighting the potential for the treatment of human cancers. Thus, the company’s first clinical candidate, DPX-Survivac, emerged.

Since then, several clinical studies have demonstrated the potential of DPX-Survivac in cancer and today the company is continuing IMV’s development in six different cancer indications across multiple phase 2 studies.

Portfolio of cancer immunotherapies

IMV’s goal is to become a leading biopharmaceutical company that develops and commercializes differentiated cancer immunotherapies that are effective, tolerable, and easy to handle in a clinical setting. The company’s current efforts are focused on leveraging the unique mechanism of action of the DPX platform to build a portfolio of cancer immunotherapies.

Developing strategic partnerships

The company intends to be opportunistic in the development of products by exploring a variety of avenues, including co-development through potential collaborations, strategic partnerships, or other transactions with third parties. IMV has expressed interest to seek additional equity and non-dilutive funding and partnerships to advance the development of the company’s product candidates.

Valuable patent portfolio

The company’s intellectual property portfolio relating to IMV’s vaccine platform technology includes 20 patent families, the first of which contains eight patents issued in five jurisdictions including the United States, Europe, Canada, Japan, and Australia. Taking into account the validations of the company’s European patents, the company’s intellectual property portfolio includes over 100 patents.

These patents have significant value and could lead to an increasing stock price in the future as the market recognizes the value that exists in the company.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Nikhil Kumar has no position in any of the stocks mentioned.

More on Investing

growing plant shoots on stacked coins
Dividend Stocks

2 Oversold TSX Dividend Stocks to Buy Now and Own for 25 Years

These top TSX dividend stocks look oversold and now offer attractive yields for TFSA and RRSP investors.

Read more »

money cash dividends

Passive-Income Power: How to Make $105/Week TAX FREE in a Bear Market

Investors may want to pursue a passive-income strategy in this bear market by snagging dividend stocks like Freehold Royalties Ltd.…

Read more »

Money growing in soil , Business success concept.
Energy Stocks

3 Growth Stocks up +30% in 2022

These three growth stocks are up over 30% in 2022 alone but have come down in the last few weeks…

Read more »

Oil pumps against sunset
Energy Stocks

2 Energy Stocks That Jumped Over 60% This Year

Consider investing in these two energy stocks amid the recent pullback after putting up stellar gains earlier this year.

Read more »

Profit dial turned up to maximum
Dividend Stocks

RRSP Investors: 2 Undervalued TSX Stocks to Buy Now for Total Returns

Top TSX dividend stocks are now on sale for RRSP investors seeking attractive total returns.

Read more »

TFSA and coins
Dividend Stocks

2 Beaten-Down Stocks to Buy for Your TFSA

Two beaten-down, but high-yield TSX stocks are profitable options for TFSA investors.

Read more »

Volatile market, stock volatility
Stocks for Beginners

3 Top TSX Stocks to Buy in Volatile Markets

Sitting on cash? Consider these three TSX stocks for the long term.

Read more »

Hand writing Time for Action concept with red marker on transparent wipe board.
Dividend Stocks

Inflation Soars to 7.7%: 1 Dividend Stock to Buy Now

Enbridge (TSX:ENB)(NYSE:ENB) stock looks like a magnificent dividend stock to help Canadians deal with inflation at 7.7%.

Read more »